HomeBUSINESS
BUSINESS

Pfizer Files Japan NDA for Next-Gen ALK Inhibitor Lorlatinib
(Jan.31.2018)

Pfizer Japan said on January 30 that it has filed its next-generation ALK/ROS1 tyrosine kinase inhibitor (TKI), lorlatinib, for the treatment of ALK-positive, unresectable, advanced/recurrent non-small cell lung cancer (NSCLC) in patients refractory or intolerant to other ALK TKIs ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 20.

News Calendar